FINWIRES · TerminalLIVE
FINWIRES

Krystal Biotech's Medicine to Treat Wounds in Dystrophic Epidermolysis Bullosa Gets Approval in UK

By

Krystal Biotech's (KRYS) beremagene geperpavec to treat wounds in patients with dystrophic epidermolysis bullosa has received approval from the UK's Medicines and Healthcare products Regulatory Agency for use from birth onward, the agency said in a Friday statement.

The medication, which is available in the form of gel, demonstrated 67% complete healing rate in a study of 31 patients at six months, according to the statement.

Dystrophic epidermolysis bullosa is a rare genetic condition characterized by fragile skin and recurrent wounds.

Price: $308.93, Change: $-7.37, Percent Change: -2.33%

Related Articles

Australia

Manulife Financial's Canada Business May Rebound Earlier, Stronger Than Expected, RBC Says

Manulife Financial's (MFC) Canada business may rebound earlier and more strongly than expected but sustained outperformance would require stronger contributions from Asia and Global Wealth and Asset Management, RBC Capital Markets said Friday.The company's Q1 core EPS was CA$1.06 ($0.77), below RBC's estimate of CA$1.11 and consensus of CA$1.10. The miss was driven by weaker-than-expected results in Canada, Corporate & Other, and Global Wealth and Asset Management, according to the note.RBC lowered its core EPS estimates to CA$4.44 from CA$4.57 in 2026 and to CA$4.90 from CA$4.97 in 2027.Canada core earnings of CA$352 million were below RBC's estimate of CA$409 million. The firm expects Canada insurance experience to normalize by year-end but models Canada core earnings to decline about 6% in 2026.Corporate & Other posted a core loss of CA$115 million, larger than RBC's expected loss of CA$65 million, while GWAM core earnings of CA$448 million also came in below forecast.RBC kept an outperform rating on Manulife Financial with a price target of CA$55.Price: $37.52, Change: $-0.02, Percent Change: -0.05%

$MFC
Australia

Gambling.com Shares Fall After Guidance Cut

Gambling.com (GAMB) shares were down over 41% in Friday trading after the company lowered its 2026 guidance.Late Thursday, the firm said it now expects 2026 revenue of $165 million to $170 million and adjusted EBITDA of $45 million to $50 million.Previously, it expected revenue of $170 million to $180 million and adjusted EBITDA of $50 million to $58 million for the year.Analysts expected revenue of $172 million in a FactSet poll.The company also reported a Q1 adjusted EPS of $0.09 on revenue $40.4 million. Analysts expected $40.2 million revenue.The firm also said it will undertake an AI-driven restructuring that includes cutting its workforce by 25%, a move expected to generate $13 million in annualized savings.After the results, Benchmark rated the stock a speculative buy, against buy previously, and cut its price target to $4 from $6.Price: $2.41, Change: $-1.74, Percent Change: -41.91%

$GAMB
Australia

Canada Goose Unlikely to See Meaninful Upside in Coming Quarters, UBS Says

Canada Goose (GOOS) may struggle to generate meaningful upside in the coming quarters as weak revenue growth and macro uncertainty continue to cloud the outlook, UBS said in a note emailed Friday.The brokerage said it sees "few catalysts ahead" for the stock, noting that investors are unlikely to get major new data points before the company's fiscal Q2 report later this year because of the seasonal nature of the business.UBS added that North American traffic remains choppy, while Europe could face pressure from slowing tourist demand.At the same time, UBS said Canada Goose is making progress in areas including wholesale execution, store operations and merchandising.UBS maintained its fiscal 2027 to 2029 earnings estimates, saying the company can still gradually improve margins over the longer term as it expands internationally and grows newer categories.UBS maintained its neutral rating and $12 price target.Price: $9.68, Change: $-0.21, Percent Change: -2.12%

$GOOS